Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 5/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666060 | 0.94 | MEN1 (0.55) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL5654279 | 0.90 | HTR1A (0.52) | MEN1KMT2ADRD4HTR1AADRA1A | |
| SCHEMBL5656387 | 0.86 | HTR1A (0.61) | MEN1KMT2ADRD2DRD4HTR1A | |
| SCHEMBL5655788 | 0.85 | POLB (0.51) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL5656003 | 0.85 | KCNH2 (0.52) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL5655893 | 0.85 | MEN1 (0.52) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL5655926 | 0.84 | DRD2 (0.55) | MEN1KMT2ADRD2DRD3HTR1A | |
| SCHEMBL5657057 | 0.83 | HTR1A (0.55) | MEN1KMT2ADRD4HTR1AADRA1A | |
| SCHEMBL5655859 | 0.83 | GFER (0.55) | MEN1KMT2ADRD4DRD3HTR1A | |
| SCHEMBL5654959 | 0.82 | HTR1A (0.55) | MEN1KMT2ADRD4HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | MEN1 3474/4885KMT2A 2124/4885DRD2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.